News
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting
April 24, 2024
Read MoreABOUT US
We are pioneers in cell and gene therapy
Leading the next generation of engineered therapeutics
Our Platform
Our proprietary
cytoDRiVE platform
Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule
OBSIDIAN CAREERS
Join Our Team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.